Rheumatoid Vasculitis

Necrotizing VASCULITIS of small and medium size vessels, developing as a complication in RHEUMATOID ARTHRITIS patients. It is characterized by peripheral vascular lesions, cutaneous ULCERS, peripheral GANGRENE, and MONONEURITIS MULTIPLEX.

Also Known As:

Networked: 183 relevant articles (12 outcomes, 11 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Rheumatoid Arthritis
2.	Amyloidosis
3.	Interstitial Nephritis (Tubulointerstitial Nephritis)
4.	Vasculitis (Vasculitides)
5.	Arthritis (Polyarthritis)

Experts

1.	Matteson, Eric L: 4 articles (01/2015 - 05/2004)
2.	Turesson, Carl: 3 articles (01/2009 - 05/2004)
3.	Makol, Ashima: 2 articles (01/2020 - 01/2015)
4.	Warrington, Kenneth J: 2 articles (01/2020 - 01/2015)
5.	Hirata, Ken-Ichi: 2 articles (11/2019 - 01/2019)
6.	Morinobu, Akio: 2 articles (11/2019 - 01/2019)
7.	Tanaka, Hidekazu: 2 articles (11/2019 - 01/2019)
8.	Bertolo, Manoel Barros: 2 articles (06/2015 - 05/2012)
9.	Nishimura, Wester Eidi: 2 articles (06/2015 - 05/2012)
10.	Sumida, Keiichi: 2 articles (01/2015 - 01/2011)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Rheumatoid Vasculitis:

1.	Immunoglobulin G (IgG)IBA 05/01/1991 - "When patient groups were formed according to the results of longitudinal studies, however, degradation of aggregated IgG mediated by Fc and (Fc + C) receptors was significantly decreased in patients with rheumatoid vasculitis and in patients with active RA in comparison with patients with inactive RA and healthy controls. " 05/01/1991 - "To investigate whether a relation exists between the receptor mediated degradation of aggregated IgG by adherent monocytes and disease activity a longitudinal study was performed in 79 patients with RA and rheumatoid vasculitis over a period of 16 months. " 11/01/1991 - "In this study we made use of an ELISA and immunoblot technique (IBT) to further characterize AEA of the IgG class in serum of patients with rheumatoid vasculitis (RV) and to investigate the relationship between the presence of IgG-AEA and vasculitis. " 08/01/1987 - "Adherent monocytes from 33 patients with active rheumatoid arthritis (RA) and rheumatoid vasculitis, 32 patients with inactive RA alone, and 20 healthy controls were incubated with 125I-aggregated IgG (125I-AIgG) of restricted size with or without fresh serum. " 06/27/1981 - "Further studies of complement- and Fc-mediated monocyte phagocytosis in which the rate constants (Kc and KFc respectively) were determined using complement-coated Saccharomyces cerevisiae and Candida albicans opsonised with IgG in monocytes from nine patients with rheumatoid vasculitis and 12 controls showed a significant reduction in Kc (p less than 0.01) but normal KFc. "
2.	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/01/2015 - "The incidence of rheumatoid vasculitis has declined significantly in the past several decades, but morbidity and mortality continue to remain high, despite aggressive treatment with cyclophosphamide or biologic agents. " 10/14/1988 - "Cyclophosphamide is generally considered too toxic for use in patients with rheumatoid arthritis, although it may be helpful in patients with systemic rheumatoid vasculitis or patients who have failed all other therapies.(ABSTRACT TRUNCATED AT 400 WORDS)" 01/01/1990 - "Fifteen patients suffering from severe systemic diseases were treated with monthly pulses administration of cyclophosphamide (0.7 g/m2 of body surface): 8 acute systemic lupus erythematosus, 2 Wegener's granulomatous, 1 polyarteritis nodosa, 1 rheumatoid vasculitis, 1 progressive systemic sclerosis, 1 relapsing uveitis and 1 dermatopolymyositis. " 09/01/1980 - "Thus, circulating immune complexes appear to be involved in the immunopathogenesis of rheumatoid vasculitis, which can be successfully treated with cyclophosphamide." 09/01/1980 - "A study of five patients with severe rheumatoid vasculitis treated with cyclophosphamide was undertaken to determine whether immune complexes were present in serum and if their levels correlated with disease activity and response to treatment. "
3.	Antigen-Antibody Complex (Immune Complex)IBA 12/01/2002 - "Rheumatoid vasculitis has been understood to be the result of severe disease extending beyond the joint, possibly caused by immune complex deposition. " 01/01/2001 - "Immune complexes (IC) are frequently detected in patients with rheumatoid vasculitis (RV). " 05/01/1994 - "Rheumatoid vasculitis has been understood to be the result of severe disease extending beyond the joint, possibly caused by immune complex deposition. " 08/01/1988 - "Immune complexes in sera from patients with rheumatoid vasculitis induce polymorphonuclear cell-mediated injury to endothelial cells." 01/01/1984 - "In systemic immune complex (IC) diseases such as SLE and rheumatoid vasculitis, IC accumulate in a number of tissues, either after deposition from the circulation or from in situ formation. "
4.	Complement System Proteins (Complement)IBA 01/01/1990 - "Complement-mediated inhibition of immune precipitation in rheumatoid vasculitis." 07/18/1981 - "Complement-mediated phagocytosis in rheumatoid vasculitis." 04/01/2013 - "Significant positive correlations of CD4+ T lymphocytopenia with other risk factors (parotid swelling, vasculitis, rheumatoid factors, low complement, cryoglobulinemia) were detected. " 01/01/1990 - "Complement-mediated inhibition of immune precipitation (CMIP) was measured in patients with rheumatoid arthritis (RA), rheumatoid vasculitis (RA VASC), patients with skin vasculitis not associated with a systemic connective tissue disease and normal healthy controls. " 06/27/1981 - "Further studies of complement- and Fc-mediated monocyte phagocytosis in which the rate constants (Kc and KFc respectively) were determined using complement-coated Saccharomyces cerevisiae and Candida albicans opsonised with IgG in monocytes from nine patients with rheumatoid vasculitis and 12 controls showed a significant reduction in Kc (p less than 0.01) but normal KFc. "
5.	Methotrexate (Mexate)FDA LinkGeneric 01/01/1992 - "Systemic rheumatoid vasculitis after discontinuation of methotrexate therapy." 10/01/2016 - "The incidence of systemic rheumatoid vasculitis has declined significantly following the general early use of methotrexate in the 1990s, and it is now a rare form of vasculitis. " 06/01/2016 - "Methotrexate-associated EBV-positive vasculitis in the skin: a report of two cases simulating rheumatoid vasculitis." 01/01/2016 - "Rheumatoid vasculitis was diagnosed, and the patient began treatment with prednisolone and methotrexate, which improved his condition. " 05/01/2004 - "Previous uncontrolled or nonrandomized studies favor the use of cyclophosphamide in patients with systemic rheumatoid vasculitis, and methotrexate in the case of other manifestations of extra-articular rheumatoid arthritis. "
6.	Azathioprine (Imuran)FDA LinkGeneric 11/01/1973 - "Proceedings: Controlled trial of azathioprine in rheumatoid vasculitis." 11/01/1991 - "We conclude that the combination of prednisone and azathioprine is effective in the treatment of severe systemic rheumatoid vasculitis; rheumatoid vasculitis with only cutaneous manifestations has a relatively good prognosis, and there is probably no indication for therapy specifically directed at the vasculitic process." 11/01/1991 - "The therapeutic effect of prednisone combined with azathioprine was studied in 28 patients with rheumatoid vasculitis. "
7.	Rituximab (Mabthera)FDA Link 01/01/2020 - "To characterize the indication, outcomes, and adverse effects of rituximab (RTX) treatment in a large single-center cohort of patients with systemic rheumatoid vasculitis (RV). " 03/12/2014 - "Regarding the treatment of rheumatoid vasculitis, rituximab looks promising. " 03/01/2012 - "We assessed the efficacy and safety of rituximab in a real-life clinical setting among patients with systemic rheumatoid vasculitis (SRV). " 01/01/2020 - "Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes, and Adverse Events." 01/01/2010 - "To test the efficacy of treatment with rituximab in refractory rheumatoid vasculitis in patients with rheumatoid arthritis (RA). "
8.	Immunoglobulin M (IgM)IBA 08/01/1980 - "Patients with active rheumatoid arthritis had significantly more 7S IgM than those with inactive disease, but there was no significant difference between those patients with and without rheumatoid vasculitis. " 10/01/1987 - "Laboratory data provided little prognostic information with regard to rheumatoid vasculitis, with the exception that IgM and IgG rheumatoid factors were significantly higher among patients with fatal course of disease than in those who achieved remission." 06/01/1981 - "High levels were seen in RA, particularly in rheumatoid vasculitis and Felty's syndrome, and significant correlations occurred between LMW IgM and the rheumatoid factor (RF) level and other indices that reflected active or severe disease. " 03/01/1986 - "Serum IgA and IgM RF from patients with rheumatoid arthritis or the sicca syndrome showed considerable charge heterogeneity whereas IgM RF from mixed cryoglobulinaemia or rheumatoid vasculitis patients showed monoclonal and oligoclonal banding patterns respectively. " 10/01/1985 - "Rheumatoid vasculitis is an example of the latter type of arteritis associated with high-titer 19S IgM rheumatoid factor typically occurring in patients with long-standing erosive rheumatoid arthritis. "
9.	Penicillamine (Cuprimine)FDA Link 05/01/1990 - "Most clinical experience in managing more symptomatic rheumatoid vasculitis has focused on glucocorticosteroids, D-penicillamine, and cytotoxic immunosuppressive drugs.(ABSTRACT TRUNCATED AT 400 WORDS)" 05/01/1979 - "D-penicillamine in the treatment of rheumatoid vasculitis." 01/01/1985 - "A patient with advanced rheumatoid arthritis and severe clinical manifestations of rheumatoid vasculitis died of acute renal failure after 30 months of treatment with high-dosage D-penicillamine. " 12/30/1983 - "Conditions often associated with rheumatoid arthritis and also thought to have an immunologic basis, such as Sjögren's syndrome, Felty's syndrome, and rheumatoid vasculitis, and reactions to medications, such as gold and penicillamine, reveal an interesting spectrum of immunogenetic relationships. " 03/01/1994 - "In particular, we describe renal syndromes associated with non-steroidal antiinflammatory drugs, remission-inducing agents (gold and penicillamine) and cytotoxic drugs, secondary amyloidosis, systemic rheumatoid vasculitis, glomerular and tubulo-interstitial nephritis not related to drug therapy."
10.	Proteins (Proteins, Gene)FDA Link 12/01/2001 - "The medical literature was reviewed from 1985 to 2001 with the assistance of a MEDLINE search using the key words vascular disease, smoking, protein p53, RA, rheumatoid vasculitis, cancer, and malignancies. " 06/01/2004 - "The first group includes lupus enteritis and protein-losing gastroenteropathy in systemic lupus erythematosus (SLE), reflux esophagitis, chronic intestinal pseudo-obstruction, and pneumatosis cystoids intestinalis in systemic sclerosis, amyloidosis in rheumatoid arthritis, bowel ulcer and bleeding in rheumatoid vasculitis and microscopic polyangiitis, and ileocecal ulcer in Behcet disease. " 05/01/1998 - "Previous 13 reported cases of cerebral infarction complicating rheumatoid vasculitis were mostly described as showing multiple infarctions in cerebral hemisphere, disturbance of consciousness, elevated protein in CSF, and effectiveness of steroid therapy. " 08/01/2012 - "We report a case of rheumatoid vasculitis (RV) that responded well to abatacept, a cytotoxic T lymphocyte-associated antigen 4 (CTLA4)-immunoglobulin fusion protein. "

Therapies and Procedures

1.	Therapeutics 11/01/2016 - "In this case report, we have presented rare and chronic protracted presentation of rheumatoid vasculitis involving skin, nerves, brain and testis, which was refractory to the recommended therapies." 01/01/2015 - "This review provides an update on the epidemiology, clinical correlates, predictors, therapy and outcomes of rheumatoid vasculitis over the past decade. " 12/01/2002 - "Therapy depends upon the clinical manifestation of rheumatoid vasculitis. " 05/01/1990 - "Therapy depends upon the clinical manifestation of rheumatoid vasculitis. " 04/01/1984 - "Our preliminary results suggest that plasmapheresis, used as an acute treatment modality, and combined with prolonged therapy with immunosuppressive drugs, may reduce the morbidity associated with certain manifestations of rheumatoid vasculitis."
2.	Plasmapheresis 04/01/1984 - "The combined effects of plasmapheresis and immunosuppressive therapy in the treatment of rheumatoid vasculitis was evaluated in 8 patients. " 04/01/1984 - "Our preliminary results suggest that plasmapheresis, used as an acute treatment modality, and combined with prolonged therapy with immunosuppressive drugs, may reduce the morbidity associated with certain manifestations of rheumatoid vasculitis." 04/01/1984 - "Efficacy of combined therapy with plasmapheresis and immunosuppressants in rheumatoid vasculitis." 12/01/1983 - "Other clinical manifestations considered as reflecting rheumatoid vasculitis (gangrene, mononeuritis multiplex, ulcers) were thought to worsen prognosis and would have been managed more often with corticosteroids, D-penicillamine, cytotoxic agents or plasmapheresis. "
3.	Drug Therapy (Chemotherapy) 01/01/1993 - "This case suggests an association between antecedent RA and splenic lymphoma, the influence of splenectomy and chemotherapy on occurrence of rheumatoid vasculitis, and a causal relationship between CPM and bladder cancer." 03/01/1994 - "In particular, we describe renal syndromes associated with non-steroidal antiinflammatory drugs, remission-inducing agents (gold and penicillamine) and cytotoxic drugs, secondary amyloidosis, systemic rheumatoid vasculitis, glomerular and tubulo-interstitial nephritis not related to drug therapy."
4.	Lasers (Laser) 12/01/2007 - "In search of a noninvasive diagnostic test for rheumatoid vasculitis (RV), this study addressed the questions whether changes in capillary blood cell velocity (CBV) detected by laser Doppler anemometry in patients with rheumatoid arthritis (RA) were correlated with the levels of soluble adhesion molecules and whether cutaneous flow abnormalities may reflect extraarticular manifestations in RA. "
5.	Plasma Exchange 01/01/1985 - "Four of 4 (100%) rheumatoid vasculitis patients treated by cryofiltration and 4 of 7 (57.1%) patients treated with plasma exchange showed clinical improvement. " 01/01/1983 - "Bullous and pustular rheumatoid vasculitis: treatment by plasma exchange." 01/01/1982 - "Plasma exchange in two patients with rheumatoid vasculitis." 11/01/1981 - "Plasma exchange in rheumatoid vasculitis." 05/01/1981 - "Plasma exchange (PE) was used to treat 9 patients with rheumatoid vasculitis. "